Aclaris Therapeutics ACRS Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's accrued expenses and other liabilities?
- Aclaris Therapeutics (ACRS) reported accrued expenses and other liabilities of -$3.03M in Q1 2026.
- How has Aclaris Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Aclaris Therapeutics's accrued expenses and other liabilities increased by 72.6% year-over-year, from -$11.04M to -$3.03M.